CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Audeo Oncology Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Audeo Oncology Inc
Suite 2040, 100 Pine Street
Phone: (415) 984-0300p:415 984-0300 SAN FRANCISCO, CA  94111  United States Fax: (302) 655-5049f:302 655-5049

Audeo Oncology Inc Inc filed a Registration Withdrawal Request of its Form S-1 (File No. 333-182568) with the SEC on 2/13/2014. The Company is seeking withdrawal of the Registration Statement as it has determined not to proceed with an offering at this time.

Business Summary
Audeo Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is primarily focused on utilizing its hyaluronic acid chemotransport technology (HyACT) to target cancer drugs primarily to tumor cells to enhance drug activity. HyACT is a platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. HyACT product candidate, HA-Irinotecan, as of June 30, 2012, was in a pivotal Phase III clinical trial for metastatic colorectal cancer (mCRC). HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer (SCLC). The Company also had two other HyACT product candidates that has completed Phase I clinical trials. The Company’s product candidate is HyACT-targeted irinotecan (HA-Irinotecan) for the treatment of mCRC. HyACT uses hyaluronic acid (HA), which delivers additional drug to the tumor and promotes uptake of the drug into the tumor cells.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/20126/30/2012YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Stephen A.Hill 56 6/1/2012 6/1/2012
President, Chief Executive Officer, Director PeterSmith 49 6/1/2012 6/1/2012
Chief Financial Officer, Secretary Charles E.Walker 6/1/2012 6/1/2012
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Alchemia Oncology Pty Limited
Audeo Discovery Pty Limited

General Information
Stock Exchange: NASD
Federal Tax Id: 800823961
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023